What this means
This is a planned trial of a shingles vaccine called SYS6017 made with mRNA. It has not started yet, so no results exist, and it cannot yet show whether the vaccine works or is safe.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 40 and over
- Where
- Not listed
The science
- Registered title
- Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above
- Trial ID
- NCT07354659 ↗
- Phase
- PHASE 2
- Study type
- interventional
- Conditions
- Herpes Zoster
- What is tested
- A zoster mRNA vaccine SYS6017, Placebo, Active Comparator Vaccine
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
- Ages
- 40 Years to no maximum
- Dates
- First posted Jan 21, 2026 · updated Jan 21, 2026
Registry summary
Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging. Vaccination plays a key role in reducing the disease burden of zoster and the associated complications. We are conducting a study entitled "A Randomized, Blinded, Placebo- and Active-Controlled, Adaptive Phase 2 Clinical Trial to Evaluate the Immunogenicity and Safety of SYS6017 (a Herpes Zoster mRNA Vaccine) in Healthy Participants Aged 40 Years and Above".